Hypolipidemic effect and mechanism of Arisaema Cum Bile based on gut microbiota and metabolomics.
10.19540/j.cnki.cjcmm.20241218.301
- Author:
Peng ZHANG
1
;
Fa-Zhi SU
1
;
En-Lin ZHU
2
;
Chen-Xi BAI
1
;
Bao-Wu ZHANG
1
;
Yan-Ping SUN
1
;
Hai-Xue KUANG
1
;
Qiu-Hong WANG
3
Author Information
1. Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education, Heilongjiang University of Chinese Medicine Harbin 150040, China.
2. Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine Guangzhou 510006, China.
3. Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education, Heilongjiang University of Chinese Medicine Harbin 150040, China Department of Chinese Materia Medica Processing, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China.
- Publication Type:Journal Article
- Keywords:
Arisaema Cum Bile;
gut microbiota;
hyperlipidemia;
lipid-lowering effect;
metabolomics
- MeSH:
Animals;
Gastrointestinal Microbiome/drug effects*;
Rats;
Male;
Metabolomics;
Hyperlipidemias/microbiology*;
Drugs, Chinese Herbal/administration & dosage*;
Rats, Sprague-Dawley;
Hypolipidemic Agents/pharmacology*;
Liver/metabolism*;
Humans;
Alanine Transaminase/metabolism*;
Triglycerides/metabolism*;
Aspartate Aminotransferases/metabolism*
- From:
China Journal of Chinese Materia Medica
2025;50(6):1544-1557
- CountryChina
- Language:Chinese
-
Abstract:
Based on the high-fat diet-induced hyperlipidemia rat model, this study aimed to evaluate the lipid-lowering effect of Arisaema Cum Bile and explore its mechanisms, providing experimental evidence for its clinical application. Biochemical analysis was used to detect serum levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), triglycerides(TG), and total cholesterol(TC) to assess the lipid-lowering activity of Arisaema Cum Bile. Additionally, 16S rDNA sequencing and metabolomics techniques were employed to jointly elucidate the lipid-lowering mechanisms of Arisaema Cum Bile. The experimental results showed that high-dose Arisaema Cum Bile(PBA-H) significantly reduced serum ALT, AST, LDL-C, TG, and TC levels(P<0.01), and significantly increased HDL-C levels(P<0.01). The effect was similar to that of fenofibrate, with no significant difference. Furthermore, Arisaema Cum Bile significantly alleviated hepatocyte ballooning and mitigated fatty degeneration in liver tissues. As indicated by 16S rDNA sequencing results, PBA-H significantly enhanced both alpha and beta diversity of the gut microbiota in the model rats, notably increasing the relative abundance of Akkermansia and Subdoligranulum species(P<0.01). Liver metabolomics analysis revealed that PBA-H primarily regulated pathways involved in arachidonic acid metabolism, vitamin B_6 metabolism, and steroid biosynthesis. In summary, Arisaema Cum Bile significantly improved abnormal blood lipid levels and liver pathology induced by a high-fat diet, regulated hepatic metabolic disorders, and improved the abundance and structural composition of gut microbiota, thereby exerting its lipid-lowering effect. The findings of this study provide experimental evidence for the clinical application of Arisaema Cum Bile and the treatment of hyperlipidemia.
